Search company, investor...

Vitatex

vitatex.com

Stage

Acquired | Acquired

About Vitatex

Vitatex is a biotech company, focused on commercializing rare cell-enrichment research and diagnostic products. The company believe that the company's products can provide R&D and clinical benefits. The company's products help researchers obtain target cells, genes and gene products that may help develop new diagnostic and therapeutic products.

Headquarters Location

25 Health Sciences Drive Suite 220 124

Stony Brook, New York, 11790,

United States

631-444-8888

Missing: Vitatex's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Vitatex's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Latest Vitatex News

Global Microarray Market Report 2022: Featuring Geron, Epic Sciences Inc., Genexine, Commence Bio and Vitatex Inc - ResearchAndMarkets.com

Oct 31, 2022

This report incorporates an in-depth analysis of the microarray market, including market estimations and trends through 2021. Major players, competitive intelligence, innovative technologies, market dynamics and regional opportunities are discussed in detail. The report examines recent developments and product portfolios of major players. The patent analysis focuses on technological trends in recent years in regions such as the U.S., Europe and Japan. The report presents a market analysis and estimates the compound annual growth rate (CAGR) for medical device technologies. A rise in ongoing R&D, increase in government spending, growing healthcare expenditures, the need for early cancer detection and diagnosis and large-scale DNA/gene chip initiatives are expected to drive the market for microarrays. In addition, the adoption of personalized medicines, a wider range of application areas and technological advances are expected to drive the demand for microarrays. However, the complexity of data obtained through DNA microarray analysis and the lack of skilled professionals are some of the major factors restraining the growth of the global microarray market. The scope of the report is limited to only those microarray markets that generate the most global revenue. Genomics and proteomics and the NGS market are already covered in other BCC Research reports, so these have been excluded. This report segments the global market by these geographic regions: North America, Europe, Asia-Pacific and the Rest of the World region. For market estimates, data is provided for the base year 2021, and forecast through 2027. Report Includes A comprehensive overview and up-to-date analysis of the global microarray market Analyses of the global market trends, with historic market revenue for 2019-2021, estimates for 2022, and projections of compound annual growth rates (CAGRs) through 2027 Highlights of the current and future market potential for global microarray industry, and areas of focus to forecast this market into various segments and sub-segments Estimation of the actual market size and revenue forecast for microarrays in USD million values, and corresponding market share analysis by product type, application and geographic region In-depth information on the major market drivers and opportunities, industry shifts and regulations, and other demographic factors that will influence this market demand in the coming years (2022-2027) Insight into the major technology updates, issues and risks, government regulations, breakthrough innovations, collaborations and developments, and costs and benefits of microarrays in the genomics industry Holistic review of the COVID-19 pandemic impact on microarray technologies market Updated information on the technology landscape of microarrays market, novel products launch, new and emerging applications in the life sciences, and ongoing clinical trials etc. Identification of the major stakeholders and analysis of the competitive landscape based on recent developments and segmental revenues

Vitatex Frequently Asked Questions (FAQ)

  • Where is Vitatex's headquarters?

    Vitatex's headquarters is located at 25 Health Sciences Drive Suite 220, Stony Brook.

  • What is Vitatex's latest funding round?

    Vitatex's latest funding round is Acquired.

  • Who are the investors of Vitatex?

    Investors of Vitatex include LineaRx and Long Island High Technology Incubator.

  • Who are Vitatex's competitors?

    Competitors of Vitatex include Acumen Pharmaceuticals, Noveome Biotherapeutics, LeadScope, Dyax, ERYtech Pharma and 13 more.

Compare Vitatex to Competitors

E
Emiliem

Emiliem operates as a biopharmaceutical company that is engaged in early oncology R&D. The company develops Molecular Targeted Therapeutics (MTTs) for oncology and other indications. MTTs are therapeutic agents that target biologically important processes central to the development and progression of cancer and other diseases. The company's clinical development strategy is focused on identifying patients most likely to respond to treatment and monitoring clinical outcome with specific biomarkers used as diagnostic assays.

O
Orphagenix

OrphageniX is a drug development company aiming to develop therapeutics for genetic diseases using advancements in "Gene Editing" technologies. OrpageniX will focus on the low volume, high margin specialty pharmaceutical niche area of "Orphan Diseases" which are protected under the Orphan Drug Act (ODA). Per the company, the OrphageniX technology can be used for diagnostics and research tools. Gene Editing uses the cell's innate repair mechanisms to repair mutations that result in genetic diseases. According to OrphaageniX, it is similar to gene therapy but avoids the risks associated with a viral vector. It works like anti-sense and RNAi, but is more efficient and permanent within the repaired cell because it changes the gene itself and not the transient message. The company states that it has major collaborations with Yale Medical School, Albert Einstein Medical Center and the University of Washington.

P
Proteome Systems

Tyrian Diagnostics is a biotechnology company that specialises in the discovery of biomarkers of disease and in diagnostic test development. The company are building a strong intellectual property portfolio to develop a pipeline of diagnostic products and establishing commercial partnerships to maximise market share and revenue generation from these products. One key avenue for commercialisation is the application of biomarkers to the company's point of need test platform, DiagnostIQTM.

L
Lifenova Biomedical SA

LIFENOVA Biomedical, S.A. was set up as a partnership between the medical & engineering community. Extensive research is being carried out in different biomedical applications, where surface properties play a key role. Among then, it can already be highlighted the results obtained on dental implants, which have already led to a implant surface with outstanding and solidly tested osseointegration characteristics.n

C
CellXplore

CellXplore is a new, biotechnology company engaged in the development of biomarker-based in vitro diagnostic assays for cancer, initially focusing on breast cancer. Although mammography is an effective screening test for early detection, there is a need for a simple, reliable and sensitive biomarker-based in vitro assay that can be used to stage and characterize breast cancer.nThe company was formed to commercialize groundbreaking discoveries demonstrating up-regulation of the ubiquitin-proteasome pathway in cancerous breast tissue, providing the capability for the noninvasive detection of breast cancer and the ability to monitor the efficacy of chemotherapeutic interventions.nCellXplore's platform technology is not restricted to breast cancer in vitro diagnostics alone, nor is it restricted to cancer diagnostics alone. Beyond cancer, CellXplore is already investigating whether similar blood sample biomarkers can be identified for the early diagnosis of several major debilitating diseases such as muscle wasting, Alzheimer's disease, Parkinson's disease and inflammatory diseases.

A
Adriacell

Adriacell s.r.l is a biotech company focused in oncology pharmaceuticals founded in Basovizza (Trieste) in March 2004 by Prof. Christian Kuehne, an Austrian citizen.nThe company is leveraging its efforts and scientific expertise to successfully solve important worldwide health problems; in particular, it has been striving to develop a new class of anti-tumour therapeutics and to create a series of powerful diagnostics for the early detection of cancer progression. The company is also developing new and highly powerful delivery solutions through small molecules as the basis for a new class of anti-infective drugs.nAdriaCell owns a patented system that can be used for the study of events subsequent to DNA double strand breaks, a very important issue for cancer research and diagnostics. Adriacell is currently evaluating a new class of therapeutics for cancer; its main lead compound is about to enter the pharmacokinetic and toxicology phases.nAdriacell Vision is to become a leader biotech drug development company concentrated in the development of solutions (treatment and diagnostics) for tumours characterized by low probability of survival for patients and of anti infective agents. Thanks to future developments in research and test activities Adriacell solutions will hopefully become useful in a wider range of pathologies.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.